

Customer case study

Dr. Jason Tonillo

Senior scientist in ADCs and targeted NBE therapeutics, Global R&D, Merck KGaA, Darmstadt, Germany. Merck is a vibrant science and technology company focused on discoveries that save and improve lives around the world.



Project goal

Characterize antibodies and antibody drug conjugates (ADCs) in terms of amino acid sequence, drug-to-antibody ratio (DAR) and post-translational modifications.

The Challenges

- Establishing a native mass spectrometry method that maintains the quaternary structure of interchain cysteine conjugated ADCs.
- Establishing a label-free method for the quantification of serum incubated ADCs.

The solution

- Top-down approach for quick confirmation of proteins, identification of common post-translational modifications and determination of the DAR.
- Bottom-up mass spectrometry for in-depth analysis of the amino acid sequence and site localization of modifications.
- BioPharmaView[™] Software automatically calculates the DAR and creates a report, which can be sent to customers without further manual changes.

The outcome

- Generic method for routine analysis of the DAR, regardless of antibody, linker and payload.
- Quick confirmation of the protein identity of small-scale expressions.

"The 6600+ system provides important data for the development of new biological drugs."

Goals

Achieve in-depth characterization of antibodies and ADCs

SCIEX products

- TripleTOF® 6600+ LC-MS/MS System
- X500R QTOF System

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to https://sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures. Trademarks and/or registered trademarks mentioned herein are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries. © 2020 DH Tech. Dev. Pte. Ltd.